Role of fibroblast growth factor-23 in calcinosis in women with systemic sclerosis.

IF 1 4区 医学 Q4 RHEUMATOLOGY
Acta reumatologica portuguesa Pub Date : 2020-10-01
Lucia Cantero-Nieto, Antonio Alvarez-Cienfuegos, Jose Alberto García-Gómez, Javier Martin, Miguel Angel González-Gay, Norberto Ortego-Centeno
{"title":"Role of fibroblast growth factor-23 in calcinosis in women with systemic sclerosis.","authors":"Lucia Cantero-Nieto,&nbsp;Antonio Alvarez-Cienfuegos,&nbsp;Jose Alberto García-Gómez,&nbsp;Javier Martin,&nbsp;Miguel Angel González-Gay,&nbsp;Norberto Ortego-Centeno","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Systemic sclerosis (SSc) is a complex disorder of unknown etiology. The purpose of this study was to evaluate fibroblast growth factor-23 (FGF-23) serum levels in women with SSc compared with healthy controls and to examine a possible association between FGF-23 serum levels with the presence of calcinosis in SSc patients.</p><p><strong>Methods: </strong>This cross-sectional study was performed in San Cecilio Hospital, Granada (Spain) from November 2017 to May 2019. Sixty-two women with SSc and 62 age and sex matched healthy controls were included in this study. FGF-23 serum concentration was evaluated by indirect enzyme-linked immunosorbent assay (ELISA).</p><p><strong>Results: </strong>There was no significant difference in FGF-23 levels between SSc patients and healthy controls (78.2 ± 60.5 vs. 80.3 ± 56.3 pg/mL, p= 0.662). Regarding the characteristics of the disease, we found a relationship between the values of FGF-23 and the presence of calcinosis. The levels of FGF-23 are higher in patients suffering from calcinosis (p= 0.028).</p><p><strong>Conclusion: </strong>We observed the presence of higher levels of serum FGF-23 in SSc female patients with calcinosis. Therefore, FGF-23 could be a possible therapeutic target for future treatments.</p>","PeriodicalId":7229,"journal":{"name":"Acta reumatologica portuguesa","volume":null,"pages":null},"PeriodicalIF":1.0000,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta reumatologica portuguesa","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: Systemic sclerosis (SSc) is a complex disorder of unknown etiology. The purpose of this study was to evaluate fibroblast growth factor-23 (FGF-23) serum levels in women with SSc compared with healthy controls and to examine a possible association between FGF-23 serum levels with the presence of calcinosis in SSc patients.

Methods: This cross-sectional study was performed in San Cecilio Hospital, Granada (Spain) from November 2017 to May 2019. Sixty-two women with SSc and 62 age and sex matched healthy controls were included in this study. FGF-23 serum concentration was evaluated by indirect enzyme-linked immunosorbent assay (ELISA).

Results: There was no significant difference in FGF-23 levels between SSc patients and healthy controls (78.2 ± 60.5 vs. 80.3 ± 56.3 pg/mL, p= 0.662). Regarding the characteristics of the disease, we found a relationship between the values of FGF-23 and the presence of calcinosis. The levels of FGF-23 are higher in patients suffering from calcinosis (p= 0.028).

Conclusion: We observed the presence of higher levels of serum FGF-23 in SSc female patients with calcinosis. Therefore, FGF-23 could be a possible therapeutic target for future treatments.

成纤维细胞生长因子-23在系统性硬化症女性钙化症中的作用。
目的:系统性硬化症(SSc)是一种病因不明的复杂疾病。本研究的目的是评估SSc女性与健康对照者的血清成纤维细胞生长因子-23 (FGF-23)水平,并研究SSc患者血清FGF-23水平与钙沉着症之间的可能关联。方法:本横断面研究于2017年11月至2019年5月在西班牙格拉纳达的圣塞西利奥医院进行。本研究包括62名SSc女性和62名年龄和性别匹配的健康对照。采用间接酶联免疫吸附试验(ELISA)评价血清FGF-23浓度。结果:SSc患者与健康对照组FGF-23水平差异无统计学意义(78.2±60.5 vs 80.3±56.3 pg/mL, p= 0.662)。关于该疾病的特征,我们发现FGF-23的值与钙沉着症的存在之间存在关系。钙质沉着症患者的FGF-23水平较高(p= 0.028)。结论:我们观察到伴有钙质沉着症的SSc女性患者血清FGF-23水平升高。因此,FGF-23可能成为未来治疗的潜在靶点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Acta reumatologica portuguesa
Acta reumatologica portuguesa 医学-风湿病学
自引率
0.00%
发文量
0
审稿时长
>12 weeks
期刊介绍: Acta Reumatólogica Portuguesa is a scientific peer reviewed journal covering all aspects of rheumatic diseases and related to Rheumatology. The journal publishes original articles, reviews, clinical cases, images in rheumatology, letters to the editor and clinical teaching (e.g. guidelines and clinical protocols). Published since 1973, Acta Reumatológica Portuguesa is the official scientific publication of the Portuguese Society of Rheumatology, a non-profit organization that promotes the knowledge and investigation of rheumatic diseases and the development of Rheumatology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信